ERBB2 and breast carcinoma: Aberrant activation of MAPK signaling is commonly observed in breast cancer, often as a result of upstream mutations (e.g., RAS, BRAF), receptor overexpression (e.g., EGFR, HER2), or cross-talk with hormone receptor signaling [22].